Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: Analysis of return to function and patient preference

Headache

Volumn 45, Issue 9, 2005, Pages 1140-1150

  Pascual, Julio ^a   García Moncó, Carlos ^b   Roig, Carles ^c   Izquierdo, Antonio Yusta ^d   López Gil, Arturo ^e,f  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^e AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

5 HT1B 1D receptor agonist; Functional disability; Migraine; Nontriptan therapy; Rizatriptan; Triptan

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; CODEINE; DIPYRONE; ERGOT ALKALOID; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIZATRIPTAN; SEROTONIN AGONIST; TRIAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANALGESIA; ARTICLE; BED REST; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DRUG EFFICACY; FEMALE; FUNCTIONAL DISEASE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; MULTICENTER STUDY; OPEN STUDY; PAIN ASSESSMENT; PATIENT DECISION MAKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; COMPARATIVE STUDY; CONVALESCENCE; MIDDLE AGED; MIGRAINE; PATIENT SATISFACTION;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PATIENT SATISFACTION; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 29144446970     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2005.00237.x     Document Type: Article

References (31)

1. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
2. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med. 2002;346:257-270.
3. Lipton RB, Scher AI, Kolodner K, Liberman J, Steiner TJ, Stewart WF. Migraine in the United States: epidemiology and patterns of health care use. Neurology. 2002;58:885-894.
4. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs. 2002;16(suppl 1):13-18.
5. Steiner TJ, Scher AI, Stewart WF, Kolodner K, Liberman J, Lipton RB. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia. 2003;23:519-527.
6. Santanello NC, Davies G, Allen C, Kramer M, Lipton R. Determinants of migraine-specific quality of life. Cephalalgia. 2002;22:680-685.
7. Caro G, Caro JJ, O'Brien JA, Anton S, Jackson J. Migraine therapy: development and testing of a patient preference questionnaire. Headache. 1998;38:602-607.
8. Menken M, Munsat TL, Toole JF. The global burden of disease study: implications for neurology. Arch Neurol. 2000;57:418-420.
9. Tfelt-Hansen P, Block G, Dahlöf C, et al. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia. 2000;20:765-786.
10. Magnusson JE, Becker WJ. Migraine frequency and intensity: relationship with disability and psychological factors. Headache. 2003;43:1049-1059.
11. 1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002;22:633-658.
12. Holmes WF, MacGregor A, Sawyer JPC, Lipton RB. Information about migraine disability influences physicians' perceptions of illness severity and treatment needs. Headache. 2001;41:343-350.
13. Lipton RB, Amatniek JC, Ferrari MD, Gross M. Migraine: identifying and removing barriers to care. Neurology. 1994;44(suppl 4):S63-S68.
14. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology. 2003;60:441-448.
15. MacGregor EA, Brandes J, Eikermann A. Migraine prevalence and treatment patterns: the global migraine and zolmitriptan evaluation survey. Headache. 2003;43:19-26.
16. Peters M, Abu-Saad HH, Vydelingum V, Dowson A, Murphy M. Migraine and chronic daily headache management: a qualitative study of patients' perceptions. Scand J Caring Sci. 2004;18:294-303.
17. Powers C, Szeto S, Pangtay D, Bort T, Cervi M, Cady R. Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. Arch Fam Med. 2000;9:753-757.
18. Loder E, Brandes JL, Silberstein S, et al. Preference comparison of rizatriptan ODT 10-mg and sumatriptan 50-mg tablet in migraine. Headache. 2001;41(8):745-753.
19. Pascual J, Bussone G, Hernandez JF, Allen C, Vrijens F, Patel K. Comparison of preference for rizatriptan 10-mg wafer versus sumatriptan 50-mg tablet in migraine. Eur Neurol. 2001;45:275-283.
20. Christie S, Göbel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Eur Neurol. 2003;49:20-29.
21. Ferrari MD, Loder E, McCarroll KA, Lines CR. Meta-analysis of rizatriptan efficacy in randomized controlled clinical trials. Cephalalgia. 2001;21:129-136.
22. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia. 1988;8(suppl 7):1-96.
23. Lipton RB, Stewart WF. Acute migraine therapy: do doctors understand what patients with migraine want from therapy? Headache. 1999;39(suppl 2):S20-S26.
24. Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(suppl 1):3-9.
25. Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000;20:554-560.
26. Block GA, Goldstein J, Polis A, Reines SA, Smith ME, and the Rizatriptan Multicenter Study Groups. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Headache. 1998;38:764-771.
27. Solomon S, Frishberg B, Hu XH, Markson L, Berger M. Migraine treatment outcomes with rizatriptan in triptan-naive patients: a naturalistic study. Clin Ther. 2001;23:886-900.
28. Cady R, Crawford G, Ahrens S, et al. Long-term efficacy and tolerability of rizatriptan wafers in migraine. Med Gen Med. 2001;3(3):1.
29. Jamieson D, Cutrer FM, Goldstein J, Dayno J, Hu XH, on behalf of the USMAP Investigators. Real-world experiences in migraine therapy with rizatriptan. Headache. 2003;43:223-230.
30. Baos V, Serrano A, Torrecilla M, et al. Patient-reported benefits of rizatriptan compared with usual non-triptan therapy for migraine in a primary care setting. Int J Clin Pract. 2003;57:761-768.
31. Bussone G, D'Amico D, McCarroll KA, Gerth W, Lines CR. Restoring migraine sufferers' ability to function normally: a comparison of rizatriptan and other triptans in randomized trials. Eur Neurol. 2002;48:172-177.